Cathie Wood has a reputation for big wagers on technology, and she earned her reputation after returning 153% in 2020. She did well in 2021 too, but the spotlight slowly moved away as most tech-related stocks did not do well in late 2021 and performed badly through 2022.

Cathie Wood, head of ARK Investment Management, usually targets tech stocks that she says have a disruptive impact, even if the company is not profitable yet. She is buying more shares of one of her favorite artificial intelligence positions.

Cathie Wood is the founder of Ark Investment Management, which operates several exchange-traded funds (ETFs) focused on innovative technologies. In 2023, she predicted software companies would be the next big investment opportunity when it comes to artificial intelligence (AI),

Explore why the Cathie Wood stocks to buy and hold in 2025, including Palantir, Shopify, Robinhood, SoFi, and Archer Aviation

Cathie Wood is betting Donald Trump’s regulatory and growth agenda will revive the market for US initial public offerings.

Cathie Wood's ARK Invest offers several popular exchange-traded funds (ETFs), and they tend to be rather concentrated, with all of them holding three dozen or fewer stocks. The banking innovator is the sixth-largest holding in the ARK Fintech Innovation ETF (NYSEMKT: ARKF),

We recently compiled a list of the 10 Tech Stocks to Sell Now According to Cathie Wood. In this article, we are going to take a look at where Intuit Inc.

While several have criticized President Trump’s memecoin launch, Cathie Wood, CEO of ARK Invest, has come forward to defend $TRUMP.

Wood's latest move was to decrease her position in a stock that was the S&P 500 's top performer last year. The famous investor sold shares of this technology player during several recent trading sessions. Should you follow her and stay away from this player in 2025?

Cathie Wood's ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in their portfolio holdings. The trades indicate a continued interest in biotech with a notable sell-off in the healthcare services sector.